Show simple item record

dc.contributor.authorHowell, Anthony
dc.contributor.authorBarnes, Diana M
dc.contributor.authorHarland, R N
dc.contributor.authorRedford, J
dc.contributor.authorBramwell, Vivien H C
dc.contributor.authorWilkinson, M J
dc.contributor.authorSwindell, Ric
dc.contributor.authorCrowther, Derek
dc.contributor.authorSellwood, R A
dc.date.accessioned2011-03-12T23:15:07Z
dc.date.available2011-03-12T23:15:07Z
dc.date.issued1984-03-17
dc.identifier.citationSteroid-hormone receptors and survival after first relapse in breast cancer. 1984, 1 (8377):588-91 Lanceten
dc.identifier.issn0140-6736
dc.identifier.pmid6142305
dc.identifier.doi10.1016/S0140-6736(84)90995-4
dc.identifier.urihttp://hdl.handle.net/10541/124406
dc.description.abstractOestrogen receptors were measured in the primary breast tumours of 508 patients and progesterone receptors in those of 486 patients. Survival from mastectomy was significantly longer in patients with receptor-positive tumours. There was no significant difference between patients with receptor-positive and receptor-negative tumours in the relapse-free interval, but survival from first relapse was longer in patients with receptor-positive tumours. Axillary node status and tumour size indicated the probability of relapse but did not influence the length of survival after relapse. Response to tamoxifen or ovarian ablation was known in 65 of the 137 patients who relapsed. Survival from first relapse was significantly longer in patients who both responded to hormone therapy and had receptor-positive tumours. Patients who did not respond to hormone therapy and had receptor-positive tumours had the same survival characteristics as those with receptor-negative tumours who did not respond.
dc.language.isoenen
dc.subject.meshBreast Neoplasms
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshMastectomy
dc.subject.meshMelphalan
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshPrognosis
dc.subject.meshReceptors, Estrogen
dc.subject.meshReceptors, Progesterone
dc.subject.meshTamoxifen
dc.titleSteroid-hormone receptors and survival after first relapse in breast cancer.en
dc.typeArticleen
dc.identifier.eissn1474-547X
dc.contributor.departmentDepartment of Medical Oncology and Clinical Rresearch, Christie Hospital, Manchester, M20 9BXen
dc.identifier.journalLanceten
html.description.abstractOestrogen receptors were measured in the primary breast tumours of 508 patients and progesterone receptors in those of 486 patients. Survival from mastectomy was significantly longer in patients with receptor-positive tumours. There was no significant difference between patients with receptor-positive and receptor-negative tumours in the relapse-free interval, but survival from first relapse was longer in patients with receptor-positive tumours. Axillary node status and tumour size indicated the probability of relapse but did not influence the length of survival after relapse. Response to tamoxifen or ovarian ablation was known in 65 of the 137 patients who relapsed. Survival from first relapse was significantly longer in patients who both responded to hormone therapy and had receptor-positive tumours. Patients who did not respond to hormone therapy and had receptor-positive tumours had the same survival characteristics as those with receptor-negative tumours who did not respond.


Files in this item

This item appears in the following Collection(s)

Show simple item record